A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Starting soon
Conditions studied: Hypertension
In brief
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).
Key facts
- Study ID
- NCT07465666
- Run by
- Novartis Pharmaceuticals
- People needed
- 500
- Starts
- 2026-08-01
- Expected to finish
- 2027-08-02
- Last updated by the study team
- 2026-07-22
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult male or female patients (≥18 years).
- Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association/American College of Cardiology [AHA/ACC] guidelines and/or the 2024 European Society of Cardiology [ESC] guidelines).
- Patients with documented office blood pressure ≥130/80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi.
- Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi.
- Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion.
- Patients willing to provide written informed consent to participate in the study.
You may not qualify if…
- Patients with malignant or severe hypertension (systolic blood pressure [SBP] ≥180 mmHg, diastolic blood pressure [DBP] ≥110 mmHg) at baseline.
- Patients with secondary causes of hypertension, as determined by the treating physician.
- Patients with a history of, or at risk of developing, angioedema.
- Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m\^2).
- Pregnant or lactating women.
- Patients with serum potassium level ≥5.5 mmol/L at baseline.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.